Protocol for production and purification of SARS-CoV-2 3CLpro
- STAR Protoc. 2023 Jun 16;4(2):102326. doi: 10.1016/j.xpro.2023.102326.
- 1. Department of Pharmacy and Biotechnology, University of Bologna, 40127 Bologna, Italy.
- 2. Center for Biotechnology and Interdisciplinary Sciences, Rensselaer Polytechnic Institute, Troy, NY 12180, USA; Department of Chemistry and Chemical Biology, Rensselaer Polytechnic Institute, Troy, NY 12180, USA.
- 3. Center for Biotechnology and Interdisciplinary Sciences, Rensselaer Polytechnic Institute, Troy, NY 12180, USA; Department of Biology, Rensselaer Polytechnic Institute, Troy, NY 12180, USA.
- 4. Department of Pharmacy and Biotechnology, University of Bologna, 40127 Bologna, Italy. Electronic address: [email protected].
- 5. Center for Biotechnology and Interdisciplinary Sciences, Rensselaer Polytechnic Institute, Troy, NY 12180, USA; Department of Chemistry and Chemical Biology, Rensselaer Polytechnic Institute, Troy, NY 12180, USA. Electronic address: [email protected].
3CLpro protease from SARS-CoV-2 is a primary target for COVID-19 Antiviral drug development. Here, we present a protocol for 3CLpro production in Escherichia coli. We describe steps to purify 3CLpro, expressed as a fusion with the Saccharomyces cerevisiae SUMO protein, with yields up to 120 mg L-1 following cleavage. The protocol also provides isotope-enriched samples suitable for nuclear magnetic resonance (NMR) studies. We also present methods to characterize 3CLpro by mass spectrometry, X-ray crystallography, heteronuclear NMR, and a Förster-resonance-energy-transfer-based enzyme assay. For complete details on the use and execution of this protocol, please refer to Bafna et al.1.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
target: Fluorescent DyeResearch Areas: Others